MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?
The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden standard for ensuring adequate treatment Cardiac diagnostic testing market estimated between $2 billion and $6 billion in the U.S. alone MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay…